-
Je něco špatně v tomto záznamu ?
ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity
A. Agaimy, JK. Dermawan, F. Haller, S. Semrau, N. Meidenbauer, R. Stoehr, S. Lax, A. Hartmann, YS. Zou, D. Xing, L. Tögel, JM. Gross, M. Michal
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, kazuistiky
NLK
ProQuest Central
od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2003-01-01 do Před 1 rokem
- MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace * MeSH
- nádorové biomarkery genetika MeSH
- nádory dělohy * genetika patologie MeSH
- proteiny S100 genetika metabolismus MeSH
- receptor erbB-2 * genetika MeSH
- receptor erbB-3 * genetika MeSH
- sarkom * genetika patologie MeSH
- stupeň nádoru MeSH
- transkripční faktory SOXE * genetika MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
With the increasing use of innovative next generation sequencing (NGS) platforms in routine diagnostic and research settings, the genetic landscape of uterine sarcomas has been dynamically evolving during the last two decades. Notably, the majority of recently recognized genotypes in uterine sarcomas represent gene fusions, while recurrent oncogene mutations of diagnostic and/ or therapeutic value have been rare. Recently, a distinctive aggressive uterine sarcoma expressing S100 and SOX10, but otherwise lacking diagnostic morphological, immunophenotypic and molecular features of other uterine malignancies has been presented in a scientific abstract form (USCAP, 2023), but detailed description and delineation of the entity is still missing. We herein describe two high-grade unclassified uterine sarcomas characterized by spindle to round cell morphology and diffuse expression of S100 and SOX10, originating in the uterine body and cervix of 53- and 45-year-old women and carrying an ERBB3 (p.Glu928Gly) and an ERBB2 (p.Val777Leu) mutation, respectively. Both tumors harbored in addition genomic HER2 amplification, ATRX mutation and CDKN2A deletion. Methylation studies revealed a methylome most similar to MPNST-like tumors, but distinct from melanoma, MPNST, clear cell sarcoma, and endometrial stromal sarcoma. Case 1 died of progressive peritoneal metastases after multiple trials of chemotherapy 47 months after diagnosis. Case 2 is a recent case who presented with a cervical mass, which was biopsied. This study defines a novel heretofore unrecognized aggressive uterine sarcoma with unique phenotypic and genotypic features. Given the potential value of targeting HER2, recognizing this tumor type is mandatory for appropriate therapeutic strategies and for better future delineation of the entity.
Biotical Laboratory Ltd Plzeň Czech Republic
Comprehensive Cancer Center European Metropolitan Area Erlangen Nuremberg Erlangen Germany
Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland Ohio USA
Department of Pathology Faculty of Medicine in Plzeň Charles University Plzeň Czech Republic
Department of Pathology The Johns Hopkins University School of Medicine Baltimore Maryland USA
School of Medicine Johannes Kepler University Linz Linz Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003688
- 003
- CZ-PrNML
- 005
- 20250206104619.0
- 007
- ta
- 008
- 250121s2024 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-024-03908-3 $2 doi
- 035 __
- $a (PubMed)39196362
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Agaimy, Abbas $u Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany. abbas.agaimy@uk-erlangen.de $u Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany. abbas.agaimy@uk-erlangen.de
- 245 10
- $a ERBB2/ ERBB3-mutated S100/ SOX10-positive unclassified high-grade uterine sarcoma: first detailed description of a novel entity / $c A. Agaimy, JK. Dermawan, F. Haller, S. Semrau, N. Meidenbauer, R. Stoehr, S. Lax, A. Hartmann, YS. Zou, D. Xing, L. Tögel, JM. Gross, M. Michal
- 520 9_
- $a With the increasing use of innovative next generation sequencing (NGS) platforms in routine diagnostic and research settings, the genetic landscape of uterine sarcomas has been dynamically evolving during the last two decades. Notably, the majority of recently recognized genotypes in uterine sarcomas represent gene fusions, while recurrent oncogene mutations of diagnostic and/ or therapeutic value have been rare. Recently, a distinctive aggressive uterine sarcoma expressing S100 and SOX10, but otherwise lacking diagnostic morphological, immunophenotypic and molecular features of other uterine malignancies has been presented in a scientific abstract form (USCAP, 2023), but detailed description and delineation of the entity is still missing. We herein describe two high-grade unclassified uterine sarcomas characterized by spindle to round cell morphology and diffuse expression of S100 and SOX10, originating in the uterine body and cervix of 53- and 45-year-old women and carrying an ERBB3 (p.Glu928Gly) and an ERBB2 (p.Val777Leu) mutation, respectively. Both tumors harbored in addition genomic HER2 amplification, ATRX mutation and CDKN2A deletion. Methylation studies revealed a methylome most similar to MPNST-like tumors, but distinct from melanoma, MPNST, clear cell sarcoma, and endometrial stromal sarcoma. Case 1 died of progressive peritoneal metastases after multiple trials of chemotherapy 47 months after diagnosis. Case 2 is a recent case who presented with a cervical mass, which was biopsied. This study defines a novel heretofore unrecognized aggressive uterine sarcoma with unique phenotypic and genotypic features. Given the potential value of targeting HER2, recognizing this tumor type is mandatory for appropriate therapeutic strategies and for better future delineation of the entity.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory dělohy $x genetika $x patologie $7 D014594
- 650 12
- $a mutace $7 D009154
- 650 12
- $a receptor erbB-2 $x genetika $7 D018719
- 650 12
- $a sarkom $x genetika $x patologie $7 D012509
- 650 12
- $a receptor erbB-3 $x genetika $7 D020893
- 650 12
- $a transkripční faktory SOXE $x genetika $7 D055757
- 650 _2
- $a proteiny S100 $x genetika $x metabolismus $7 D009418
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a stupeň nádoru $7 D060787
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Dermawan, Josephine K $u Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA
- 700 1_
- $a Haller, Florian $u Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany $u Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a Semrau, Sabine $u Department of Radiation Oncology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
- 700 1_
- $a Meidenbauer, Norbert $u Department of Internal Medicine 5-Hematology and Oncology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
- 700 1_
- $a Stoehr, Robert $u Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany $u Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a Lax, Sigurd $u Department of Pathology, Hospital Graz II, Academic Teaching Hospital of the Medical University Graz, Graz, Austria $u School of Medicine, Johannes Kepler University Linz, Linz, Austria
- 700 1_
- $a Hartmann, Arndt $u Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany $u Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a Zou, Ying S $u Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 700 1_
- $a Xing, Deyin $u Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 700 1_
- $a Tögel, Lars $u Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany $u Comprehensive Cancer Center, European Metropolitan Area Erlangen-Nuremberg (CCC ER-EMN), Erlangen, Germany
- 700 1_
- $a Gross, John M $u Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 700 1_
- $a Michal, Michael $u Department of Pathology, Faculty of Medicine in Plzeň, Charles University, Plzeň, Czech Republic $u Biotical Laboratory, Ltd, Plzeň, Czech Republic
- 773 0_
- $w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 485, č. 5 (2024), s. 805-813
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39196362 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104614 $b ABA008
- 999 __
- $a ok $b bmc $g 2263444 $s 1239695
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 485 $c 5 $d 805-813 $e 20240828 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- LZP __
- $a Pubmed-20250121
